Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Peter Clark, MA, MD, FRCP: A Payer Perspective

Feb

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Peter Clark, MA, MD, FRCP: A Payer Perspective

Adjuvant Durvalumab in Resected Early-Stage NSCLC

Ultrasound-Guided DOT May Reduce Unnecessary Breast Biopsies by Nearly 25

AACR Announces Fellows of the AACR Academy Class of 2026

Extended Endocrine Therapy in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer

Consensus Recommendations Developed for Use of Liquid Nitrogen Spray Cryotherapy in Barrett Esophagus Esophageal Cancer